Pfizer's JN.1 vaccine has been the only option available to Australians since the start of the year. Here's what happened to ...

BofA forecasts slowing overall revenue, estimating about $1 billion in 2025, slightly below the company’s guidance. It ...

Novavax, Inc. (NASDAQ:NVAX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company’s non-mRNA COVID-19 vaccine is ...

Novavax (NVAX) downgraded to Underperform by BofA due to uncertain growth outlook despite cost-cutting measures. Read more ...

Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.

On Wednesday, Novavax Inc. (NASDAQ:NVAX) reported second-quarter 2025 sales of $239.24 million, compared to $415 million a year ago, beating the consensus of $156.29 million. The company completed the ...

Bank of America’s downgrade to ‘Underperform’ with a $7 target deepened concerns over Sanofi’s limited commercialization of ...

Nuvaxovid product sales for 2025 are expected to be $610 million, and adjusted supply sales of $25-$40 million compared to prior expectation of $20 million- $35 million.

Novavax raised its full-year adjusted revenue forecast on Wednesday, betting on the strength of vaccine supply partnerships, including with Serum Institute of India and Japan's Takeda , sending its ...

Shares of the biotech were up 4.3% in premarket trading, after it also beat Wall Street expectations for second-quarter ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter ended June 30, 2025.